whatshot

IPHA   $1.8399999999999999  3.95% Market Open

Innate Pharma SA
show_chart Advanced Chart of IPHA
Last Events:

2023-08-09 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-06 Trend pattern changed from симметричный треугольник to нисходящий треугольник.

2023-08-06 Trend Power changed from almost flat to .

2023-08-05 Signal in Stochastic changed from bearish to bearish weakening. The stochastic indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: main and signal line crossing.

2023-08-05 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-05 Trend Power changed from to almost flat.

2023-08-05 Trend changed from linear down to up and flat.

2023-08-04 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

Current temperature: 7.29
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 4
Target Price Mean 8.07
Mean unverified/preliminary 8.07 / 8.07
Target Price Low / High 2.58 / 11.57
Median / STD DEV 9.06 / 3.79
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy ActivelyBuy ActivelyBuy
rsi ActivelyBuy ActivelyBuy ActivelyBuy
macd None None None
stoch None None None
ma20 None ActivelyBuy ActivelyBuy
ma50 None None None
ma100 Buy Buy ActivelyBuy
Candlestick PatternJan. 3, 2025 Hammer - is a candlestick that consists of a small body near the high with a little or no upper shadow and a long lower tail. Considered to be a bullish pattern during a downtrend.
ISIN US45781K2042
ceo Mr. Jonathan E. Dickinson
Website https://www.innate-pharma.com
Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.